

PRIOR AUTHORIZATION POLICY

POLICY: Oncology (Injectable) – Beleodaq Prior Authorization Policy

- Beleodaq® (belinostat intravenous infusion – Spectrum)

REVIEW DATE: 09/07/2022

OVERVIEW

Beleodaq, a histone deacetylase inhibitor, is indicated for the treatment of adults with relapsed or refractory **peripheral T-cell lymphoma**.¹

Guidelines

Beleodaq is addressed in the National Comprehensive Cancer Network (NCCN) **T-Cell Lymphomas** guidelines (version 2.2022 – March 7, 2022). NCCN recommends Beleodaq as a single-agent for second-line and subsequent therapy of peripheral T-cell lymphoma, breast implant-associated anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, extranodal NK/T-cell lymphoma, and hepatosplenic T-cell lymphoma.^{2,3}

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Beleodaq. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Beleodaq as well as the monitoring required for adverse events and long-term efficacy, approval requires Beleodaq to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Beleodaq is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **T-Cell Lymphoma.** Approve for 1 year if Beleodaq is prescribed by or in consultation with an oncologist or a dermatologist.
Note: Examples include peripheral T-cell lymphoma, breast implant-associated anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, extranodal NK/T-cell lymphoma.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Beleodaq is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Beleodaq® intravenous infusion [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals; April 2022.

09/07/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

2. The NCCN T-Cell Lymphomas Clinical Practice Guidelines in Oncology (version 2.2022 – March 7, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed August 30, 2022.
3. The NCCN Drugs and Biologics Compendium. © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 30, 2022. Search term: belinostat.